Asieris Pharmaceuticals (Stock Code: 688176.SH) announced that its photodynamic drug-device combination product APL-1702, for the non-surgical treatment of cervical High-Grade Squamous Intraepithelial...

Asieris Pharmaceuticals has achieved a significant milestone with the approval of CEVIRA in China, marking the first non-invasive therapy for cervical precancerous lesions.

Asieris Pharmaceuticals announces the approval of CEVIRA®, a groundbreaking non-invasive therapy for cervical precancerous lesions in China.

Asieris Pharmaceuticals celebrates the approval of CEVIRA, the first non-invasive therapy for cervical precancerous lesions in China, transforming treatment approaches.

Asieris Pharmaceuticals' 2026 Semi-Annual Report reveals significant advancements in product commercialization as the company strategically transitions into the biopharmaceutical sector.

SHANGHAI, Aug. 28, 2026 /PRNewswire/ -- Asieris Pharmaceuticals today released its 2026 Semi-Annual Report, showing comprehensive progress across all business segments. With the gradual realization of commercial launch and international expansion for its core products, the company is...

SHANGHAI, Aug. 28, 2026 /PRNewswire/ — Asieris Pharmaceuticals today released its 2026 Semi-Annual Report, showing comprehensive progress across all business segments. With the gradual realization of commercial launch and international expansion for its core products, the company is accelerating its transition from Biotech to Biopharma: CEVIRA®, the world’s first non-invasive treatment for precancerous cervical lesions[1], […]

Bladder Cancer Pipeline constitutes 80+ key companies continuously working towards developing 100+ Bladder Cancer treatment therapies, analyzes DelveInsight.

Bladder Cancer Pipeline Insights DelveInsight’s, “Bladder cancer – Pipeline Insight, 2025,” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Bladder cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Global biopharmaceutical company, Asieris Pharmaceuticals announced the signing of an investigational drug supply agreement under the Expanded Access Investigational New Drug (IND) Program with the Centers for Disease Control and Prevention (CDC) in the United States for the independently developed APL-1202 (nitroxoline), subject to evaluation by CDC experts, to be used for treating Free-living Amoebae (FLA) infections.

Improve Human Health to Preserve Patients’ Dignity Leading new drug development for genitourinary tumors & other related diseases Highlights Products Vesique®(APL-1202) | Cevira® (APL-1702) Treatment ...

SHANGHAI, January 6, 2025 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a leading global biopharmaceutical company dedicated to advancing medicines to improve genitourinary tumors and the health of women with unmet medical needs, announced the signing of a research agreement for the supply of drugs under the Expanded Access to Investigational New Drug (IND) Program and Centers for Disease Control and Prevention (The CDC) in a the United States because it was developed independently APL-1202 (nitroxoline), depending on the test by The CDC Specialists, to be used to treat Amoebae infections (FLA).

SHANGHAI, Jan. 6, 2025 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a leading global biopharmaceutical company dedicated to advancing innovative therapies for genitourinary tumors and women's health with significant unmet medical needs, announced the signing of an investigational drug supply agreement under the Expanded Access Investigational New Drug (IND) Program   with the Centers for Disease Control and Prevention (CDC) in the United States for the independently developed APL-1202 (nitroxoline), subject to evaluation by CDC experts, to be used for treating Free-living Amoebae (FLA) infections.

Global biopharmaceutical company, Asieris Pharmaceuticals announced the signing of an investigational drug supply agreement under the Expanded Access Investigational New Drug (IND) Program with the Ce...

Asieris Pharmaceuticals communicates that the EMA has accepted the application for CEVIRA, a new photodynamic therapy for HSIL. Discover what this means for treatment options in Europe.

Asieris Pharmaceuticals unveils its 2025 Semi-Annual Report, showcasing strong commercial performance and groundbreaking innovations set to launch soon.

Asieris Pharmaceuticals has announced its 2024 Annual Report, showcasing a remarkable revenue growth exceeding RMB 200 million, fueled by innovative products and strategic expansion.

Asieris Pharmaceuticals has signed a vital agreement with the CDC for APL-1202 to treat rare Free-Living Amoeba infections, enhancing patient care options.

SHANGHAI, January 6, 2025 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a leading global biopharmaceutical company dedicated to advancing innovative therapies for genitourinary tumors and women's health with significant unmet medical needs, announced the signing of a drug supply agreement investigations under the Expanded Access Investigational New Drug (IND) The program with the Centers for Disease Control and Prevention (CDC) in the United States for the independently developed APL-1202 (nitroxoline), undergoing evaluation by CDC experts, to be used to treat free-living Amoeba (FLA) infections.

SHANGHAI, January 6, 2025 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a leading global biopharmaceutical company dedicated to advancing medicines to improve genitourinary tumors and the health of women with unmet medical needs, announced the signing of a research agreement for the supply of drugs under the Expanded Access to Investigational New Drug (IND) Program and Centers for Disease Control and Prevention (The CDC) in a the United States because it was developed independently APL-1202 (nitroxoline), depending on the test by The CDC Specialists, to be used to treat Amoebae infections (FLA).

SHANGHAI, March 3, 2026 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global innovative pharmaceutical company focused on genitourinary tumors and women's health, announced today that its core product APL-1702 (trade name: CEVIRA®, Hexaminolevulinate Hydrochloride...

OSLO, Norway, March 3, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that its core product APL-1702 (trade name: CEVIRA®), has received the Drug Registration Certificate from...

OSLO, Norway, March 3, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that its core product APL-1702 (trade name: CEVIRA®), has received the Drug Registration Certificate from...

OSLO, Norway, Feb. 27, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that its marketing authorization application (MAA) for Cevira® (APL-1702) for the treatment of high-grade...